title: Value of single-photon emission-computed tomography in acute stroke therapeutic trials.
abstract: OBJECTIVE
  New therapeutic interventions for acute ischemic stroke are aimed at improving cerebral blood flow in the first 3 to 6 hours after symptom onset. Single-photon emission-computed tomography (SPECT) performed in the setting of clinical therapeutic trials may give us a better understanding of the physiological response to new forms of treatment and could impact acute management decisions.
  
  
  METHODS
  We prospectively studied 15 patients with hemispheric ischemic stroke with SPECT within 6 hours of symptom onset and again at 24 hours. The ischemic defect was assessed in a semiquantitative manner that used computer-generated regions of interest (SPECT graded scale). This measure was correlated with clinical presentation (National Institutes of Health [NIH] Stroke Scale), initial clinical course (change in NIH Stroke Scale), long-term outcome (Barthel Index at 3 months), and complications of cerebral hemorrhage and edema.
  
  
  RESULTS
  The severity of the SPECT graded scale on the admission scan correlated with the severity of neurological deficit (admission NIH Stroke Scale) (P < .05) and was positively associated with poor long-term outcome as measured with the Barthel Index (P < .001) and the complications of cerebral hemorrhage and massive cerebral edema (P < .005). In fact, there was a threshold value for the SPECT graded scale above which all patients suffered poor long-term outcome and the complications of cerebral hemorrhage and edema.
  
  
  CONCLUSIONS
  The measurement of an ischemic defect using SPECT is a valid assessment of hemispheric stroke severity in the hyperacute setting and may be useful for selecting or stratifying patients in clinical therapeutic trials.
authors.affiliation: Department of Neurology, University of Texas Health Science Center, Houston 77030.
authors.forename: S K
authors.initials: SK
authors.lastname: Hanson
authors.forename: J C
authors.initials: JC
authors.lastname: Grotta
authors.forename: H
authors.initials: H
authors.lastname: Rhoades
authors.forename: H D
authors.initials: HD
authors.lastname: Tran
authors.forename: L M
authors.initials: LM
authors.lastname: Lamki
authors.forename: B J
authors.initials: BJ
authors.lastname: Barron
authors.forename: W J
authors.initials: WJ
authors.lastname: Taylor
mesh_terms: D000208:Acute Disease; D000368:Aged; D000369:Aged, 80 and over; D001929:Brain Edema / Q000209:etiology; D002543:Cerebral Hemorrhage / Q000209:etiology; D002561:Cerebrovascular Disorders / Q000150:complications / Q000175:diagnosis / Q000000981:diagnostic imaging* / Q000628:therapy; D005260:Female; D006801:Humans; D002546:Ischemic Attack, Transient / Q000175:diagnosis / Q000000981:diagnostic imaging; D008297:Male; D008875:Middle Aged; D009316:National Institutes of Health (U.S.); D015899:Tomography, Emission-Computed, Single-Photon; D014481:United States